Digital Biomarkers Market Poised for Fourfold Growth by 2031 as Wearables Redefine Patient Monitoring

The quiet integration of sensors, smartphones, and wearable devices into everyday healthcare is fundamentally altering how clinicians track disease and how patients experience treatment. A comprehensive review of the digital biomarkers market shows global revenues climbing from an estimated USD 4.79 billion in 2024 to nearly USD 19.17 billion by 2031, a compound annual growth rate close to 22%. This near-quadrupling within seven years signals that digital biomarkers have moved decisively beyond pilot programs and into mainstream clinical practice.

At its core, this growth story is about the maturing capability of consumer-grade and clinical-grade devices to capture continuous, objective health data—heart rhythms, gait patterns, sleep architecture, speech cadence—and convert that raw signal into clinically actionable insight. What once required a hospital visit and a battery of tests can increasingly be inferred passively from a wrist-worn sensor or a smartphone application running quietly in the background.

From Episodic Care to Continuous Monitoring

Traditional healthcare delivery has long relied on periodic snapshots: an annual physical, a quarterly lab panel, an occasional specialist visit. Digital biomarkers upend this model by enabling near-continuous observation of physiological and behavioral signals, allowing clinicians to detect subtle deviations from baseline long before symptoms become clinically apparent. This capability is proving especially valuable for chronic and progressive conditions, where early detection of decline can materially alter treatment trajectories.

The shift also aligns closely with the broader movement toward personalized medicine. Rather than applying standardized treatment protocols across broad patient populations, clinicians can use individualized digital biomarker data to tailor interventions, adjust medication dosing, and time therapeutic decisions around a patient's actual physiological state rather than population averages.

Chronic Disease Burden Fuels Adoption

The scale of global chronic disease provides a powerful structural tailwind for this market. Cardiovascular conditions, cancer, chronic respiratory disease, and diabetes collectively account for the overwhelming majority of deaths worldwide each year, and all four categories benefit from continuous rather than episodic monitoring. Cardiovascular disease alone accounts for the largest share of chronic disease mortality, creating substantial demand for wearable-based cardiac monitoring tools capable of flagging arrhythmias or other warning signs in real time.

Global health authorities estimate that chronic diseases claim over 40 million lives annually, representing roughly three-quarters of deaths worldwide—a burden that continuous digital monitoring is increasingly positioned to help manage through earlier intervention.

Neurological disorders represent a particularly compelling use case. Conditions such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis are notoriously difficult to track using conventional clinical assessments, which capture only a brief snapshot during infrequent office visits. Smartphone-based digital biomarker platforms that measure tremor, gait, and cognitive response patterns allow for far more granular, longitudinal tracking of disease progression—an advance that has attracted significant pharmaceutical industry investment.

Pharma and MedTech Convergence

Perhaps the most telling sign of this market's maturation is the depth of collaboration between pharmaceutical companies and digital health technology firms. Partnerships aimed at developing condition-specific digital biomarkers—particularly for neurodegenerative disease—have become increasingly common, as drug developers seek more sensitive endpoints for clinical trials and more precise tools for post-approval monitoring. Smartphone-based systems capable of remotely assessing neurological function are enabling more frequent, more objective disease tracking than periodic in-clinic evaluation ever could.

Beyond neurology, major pharmaceutical players have launched comprehensive digital healthcare platforms that integrate biomarker data with medication delivery and provider access, effectively building end-to-end digital care ecosystems around chronic disease management for conditions including obesity, migraine, and diabetes.

Segment Insights: Wearables and Providers Take the Lead

By product type, wearable devices—smartwatches, fitness trackers, and dedicated medical-grade sensors—represent the dominant category, prized for their ability to passively and continuously capture vital health metrics without requiring active patient engagement. This convenience factor has made wearables the preferred form factor for both consumer wellness applications and clinical-grade monitoring programs alike.

By clinical application, neurological disorders currently claim the largest share of market revenue, reflecting the acute need for non-invasive, continuous tracking tools in a therapeutic area where traditional diagnostic methods fall short. Looking ahead, the monitoring segment—as opposed to diagnostics or prognostics—is expected to grow fastest, as healthcare systems increasingly prioritize long-term disease management over point-in-time diagnosis.

Healthcare providers, including hospitals, clinics, and diagnostic centers, are expected to account for the largest share of end-user revenue by 2031, driven by the operational efficiencies digital biomarkers offer: reduced readmission rates, more targeted resource allocation, and improved capacity for remote patient monitoring programs that extend care beyond hospital walls.

Regional Momentum

North America currently leads the global market, underpinned by rapid adoption of advanced healthcare technologies, a mature venture capital ecosystem actively funding digital health startups, and strong existing technology infrastructure. Dedicated institutes focused on rigorously evaluating digital health technologies have emerged to help separate genuinely effective solutions from market hype, lending additional credibility and structure to the sector's growth.

Asia-Pacific is projected to post the fastest regional growth rate through 2031, propelled by government investment in smart healthcare infrastructure across countries including Japan and South Korea, alongside a rapidly aging population. Regional demographic data indicates that the population aged 60 and above is expected to nearly double as a share of the total population by 2050, intensifying demand for continuous monitoring solutions capable of managing age-related chronic conditions including dementia and cardiovascular disease at scale.

Competitive Landscape

Key players shaping the market include AliveCor, Amgen, Biogen, Huma, Koneska Health, Evidation Health, Eli Lilly and Company, Pfizer, Novartis, and GSK, among others. Competitive dynamics increasingly center on strategic partnerships that pair pharmaceutical domain expertise with digital sensing and data analytics capabilities—an approach exemplified by recent collaborations targeting blood-based and digital biomarkers for Alzheimer's-related tau pathology, as well as infrastructure investments aimed at processing biomarker data at scale with greater flexibility across diverse algorithmic configurations.

Challenges on the Path Forward

Despite strong momentum, the market faces real friction points. Limited standardization across digital health platforms complicates data interoperability, making it difficult for healthcare systems to integrate biomarker data from multiple device manufacturers into unified clinical records. The high cost of advanced sensing technologies also remains a barrier to broader accessibility, particularly for smaller healthcare providers and resource-constrained health systems. Industry response has focused on open-source data standards and more cost-effective, scalable technology deployment models designed to widen access without compromising data quality.

Policy Support Accelerates Global Adoption

Government and multilateral institutional support has emerged as a meaningful accelerant for digital biomarker adoption worldwide. International health bodies have introduced coordinated frameworks aimed at expediting the adoption of digital health technologies in service of universal health coverage goals, complete with standardized indicators designed to track implementation progress across diverse national healthcare systems. This kind of structured policy scaffolding gives healthcare providers and technology developers a clearer regulatory pathway, reducing the uncertainty that has historically slowed digital health technology adoption in more conservative clinical settings.

National-level initiatives are reinforcing this momentum further. Dedicated funding mechanisms established specifically to evaluate digital health technologies and separate genuinely effective solutions from unsubstantiated claims are helping build the evidentiary foundation clinicians need before incorporating new digital biomarker tools into standard care pathways. This kind of rigorous, independent evaluation infrastructure is expected to play an increasingly important role in accelerating clinical trust and reimbursement decisions as the broader market matures.

From Wellness Gadget to Clinical Instrument

A defining characteristic of this market's evolution is the steady blurring of boundaries between consumer wellness devices and clinical-grade diagnostic instruments. Smartwatches and fitness trackers originally designed for casual fitness tracking increasingly incorporate features validated for clinical use, including arrhythmia detection algorithms and sleep apnea screening capabilities that were unimaginable in consumer wearables just a few years ago.

This convergence carries significant implications for how healthcare delivery is structured going forward. Rather than requiring patients to acquire separate medical-grade monitoring equipment, healthcare systems can increasingly leverage devices patients already own, dramatically lowering the barrier to continuous monitoring program enrollment. This democratization of monitoring capability is particularly consequential for underserved populations who may otherwise lack access to specialized diagnostic equipment, though questions around data accuracy standardization and clinical validation protocols remain active areas of ongoing regulatory attention.

Outlook

The digital biomarkers market's projected near-quadrupling by 2031 reflects a broader transformation in how healthcare systems define and deliver patient monitoring. As wearable technology, artificial intelligence, and regulatory frameworks continue to mature in tandem, digital biomarkers are positioned to become a standard component of chronic disease management, clinical trial design, and personalized treatment planning across the global healthcare landscape.